vascular-cell-adhesion-molecule-1-is-associated-with-immune

Vascular Cell Adhesion Molecule 1 Is Associated With Immune Remodeling, Glioma Progression, and Tumor Cell Survival in U87 and U251 Cells

The immunosuppressive microenvironment of glioma remains a major barrier to effective treatment. Vascular cell adhesion molecule 1 (VCAM1) regulates ...

Nanchang University

 Little is known about the incidence of ipilimumab-related serious adverse events (SAEs) across various tumor types, drug doses and treatment regimens.  PubMed database was searched up to November, 2017 to identify prospective clinical trials of ipilimumab therapy for adult patients with cancer. Comparisons of the incidence were based on the χ test in univariate analysis and the logistic regression model in multivariate analysis.  Twenty-four studies (4549 patients) with 35 independent study cohorts (21 melanoma, 6 prostate cancer, 5 NSCLC, and 3 SCLC cohorts) of ipilimumab were included in the meta-analysis. The overall incidence of SAEs during ipilimumab mono-therapy was 26.1% (95% CI, 21.1%-31.8%). SAEs were more frequent in the 10 mg/kg groups than in the 3 mg/kg groups (35.9% vs 17.3%; P < 0.001). Combination therapy showed significantly higher incidence than mono-therapy in melanoma (33.8% vs 25.0%; P = 0.002). After adjustment for potential confounders, multivariable analyses demonstrated lower odds of SAEs in NSCLC (odds ratio [OR] 0.52, 95% CI 0.40-0.69, P < 0.001) and SCLC (OR 0.41, 95% CI 0.31-0.54, P < 0.001) compared with melanoma. The 10mg/kg cohort presented significantly higher odds than the 3mg/kg (OR 2.84, 95% CI 2.35-3.43, P < 0.001). The combination therapy showed significantly higher odds than the mono-therapy (OR 1.38, 95% CI 1.11-1.71, P = 0.003).  The incidence of ipilimumab-related SAEs was higher in melanoma, the 10mg/kg group and during combination therapy. Clinicians should enhance awareness of these risk factors in clinical practice and carefully monitor patients.

Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis.

Programmed death receptor-1 (PD-1) and its ligand (PD-L1) inhibitors have shown promising results in treating advanced non-small-cell lung cancer (NSCLC). Our objective was to compare the relative and absolute benefits between PD-1 and PD-L1 inhibitors in advanced NSCLC.

The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.

Brain metastases (BMs) indicate poor outcomes and are commonly excluded in immunotherapy clinical trials in advanced lung cancer; moreover, the effect of BM status on immunotherapy efficacy is inconsistent and inconclusive. Therefore, we conducted a meta-analysis to assess the influence of BM status on immunotherapy efficacy in advanced lung cancer.

Brain Metastases Status and Immunotherapy Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis.

Non-muscle-invasive bladder cancer (NMIBC) is renowned for its high recurrence, invasiveness, and poor prognosis. Consequently, developing new biomarkers for risk assessment and investigating innovative therapeutic targets postoperative in NMIBC patients are crucial to aid in treatment planning.

Comprehensive analysis of single-cell and bulk RNA sequencing reveals postoperative progression markers for non-muscle invasive bladder cancer and predicts responses to immunotherapy.

This preliminary study explores the prognostic value of pretreatment peripheral serum apolipoprotein E (ApoE) in patients with non-metastatic nasopharyngeal carcinoma (NPC).

Pre-treatment serum apolipoprotein E: a promising prognostic indicator for nasopharyngeal carcinoma.

Correction: Pre-treatment serum apolipoprotein E: a promising prognostic indicator for nasopharyngeal carcinoma.

Non-small cell lung cancer (NSCLC) is the most prevalent subtype of lung cancer, accounting for approximately 85% of all lung cancer cases and remaining a major cause of cancer-related mortality worldwide. Despite advances in diagnostic and therapeutic approaches, the incidence and mortality rates of NSCLC continue to rise, especially in low-income and middle-income countries.

Expression of cancer stem cell markers and their prognostic significance in stage IIIA non-small cell lung cancer.

A chemiluminescent aptamer sensor (CL aptasensor) is  proposed for ultrasensitive determination of CYFRA21-1 as a lung cancer biomarker. The sensing mechanism of the CL aptasensor is  based on the incorporation of luminol into a cobalt-based metal-organic framework (MOF), also called ZIF-67, to generate a composite of the luminol@ZIF-67. This composite was then functionalized with a CYFRA21-1 specific aptamer (luminol@ZIF-67-apt) as signal probe. ssDNA was immobilized on PVP/NiO nanocomposite, allowing hybridization with the aptamer by complementary base pairing. In the presence of CYFRA 21-1, the luminol@ZIF-67-apt/PVP/NiO-ssDNA ternary complex could be assembled and induced intense chemiluminescence emission. Under the optimized conditions, the sensor showed a broad linear detection range  from 10⁻ to 10 ng/mL, with a detection limit (LOD) of 3.7 × 10⁻ ng/mL. Reproducibility (RSD = 3.81%) and long-term stability were observed, with signals retained to 98.22% and 97.87% over 20 and 33 days, respectively. Recovery experiments in spiked human serum samples ranged from 96.00% to 99.30%, and RSDs from 3.41% to 4.07%, indicating good stability and potential in complex biological matrices. Such a strategy holds great promise for ultrasensitive detection of CYFRA 21-1 for clinical bioanalysis.

Article	Year
Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis. Journal of Cancer\| PubMed ID: 30662532	2019
The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis. International immunopharmacology\| PubMed ID: 32759049	2020
Brain Metastases Status and Immunotherapy Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in immunology\| PubMed ID: 34335570	2021
Comprehensive analysis of single-cell and bulk RNA sequencing reveals postoperative progression markers for non-muscle invasive bladder cancer and predicts responses to immunotherapy. Discover oncology\| PubMed ID: 39532830	2024
Pre-treatment serum apolipoprotein E: a promising prognostic indicator for nasopharyngeal carcinoma. European journal of medical research\| PubMed ID: 40495209	2025
Correction: Pre-treatment serum apolipoprotein E: a promising prognostic indicator for nasopharyngeal carcinoma. European journal of medical research\| PubMed ID: 40846980	2025
Expression of cancer stem cell markers and their prognostic significance in stage IIIA non-small cell lung cancer. World journal of stem cells\| PubMed ID: 41025099	2025
Sensitive chemiluminescent determination of CYFRA 21-1 as a lung cancer marker using PVP/NiO-supported luminol@ZIF-67-aptamer composite. Mikrochimica acta\| PubMed ID: 41168491	2025

Si-Cong Jiang

Biography

JoVE Journal Publications

Other Publications